<DOC>
	<DOC>NCT01678924</DOC>
	<brief_summary>This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia (PHN).</brief_summary>
	<brief_title>A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<criteria>Postherpetic neuralgia with pain present for at least 9 months Active herpes zoster skin rash Anticipated treatment for postherpetic neuralgia during the first 3 months of the study, including oral and topical medications, acupuncture, spinal cord stimulation, transcutaneous nerve stimulation (TNS), or trigger point injection Anticipated treatment with pain medication for the treatment of postherpetic neuralgia during the first 3 months of the study Use of capsaicin treatment for postherpetic neuralgia within 6 months, or anticipated use during the first 3 months of the study Use of botulinum toxin of any serotype for any reason within 6 months, or anticipated use during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>